» Authors » Ilaria Zanotti

Ilaria Zanotti

Explore the profile of Ilaria Zanotti including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 1211
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Zaccarelli A, Mattina B, Pont L, Benavente F, Zanotti I, Cioffi F, et al.
J Agric Food Chem . 2024 Dec; 73(1):938-953. PMID: 39723940
This study presents the development of an analytical characterization strategy tailored to end products derived from an alfalfa ()-based biorefinery with particular emphasis on protein concentrates and phenolic-enriched fractions. Our...
2.
Bonilha I, Gomes E, Carmo H, Breder I, Barreto J, Breder J, et al.
Int J Mol Sci . 2024 Apr; 25(7). PMID: 38612917
Evolocumab and empagliflozin yield a modest rise in plasma high-density lipoprotein cholesterol (HDL-C) through unknown mechanisms. This study aims to assess the effect of evolocumab plus empagliflozin vs. empagliflozin alone...
3.
Carmo H, Bonilha I, Barreto J, Tognolini M, Zanotti I, Sposito A
Int J Mol Sci . 2024 Jan; 25(2). PMID: 38279290
Despite significant therapeutic advancements, morbidity and mortality following myocardial infarction (MI) remain unacceptably high. This clinical challenge is primarily attributed to two significant factors: delayed reperfusion and the myocardial injury...
4.
Giannessi L, Lupo M, Rossi I, Martina M, Vilella A, Bodria M, et al.
Eur J Med Chem . 2023 Dec; 265:116063. PMID: 38160616
Among the strategies to overcome the underperformance of statins in cardiovascular diseases (CVDs), the development of drugs targeting the Proprotein Convertase Subtilisin-like Kexin type 9 (PCSK9) is considered one of...
5.
Vilella A, Bodria M, Papotti B, Zanotti I, Zimetti F, Remaggi G, et al.
Brain Behav Immun . 2023 Nov; 115:517-534. PMID: 37967665
Background: Increasing evidence highlights the importance of novel players in Alzheimer's disease (AD) pathophysiology, including alterations of lipid metabolism and neuroinflammation. Indeed, a potential involvement of Proprotein convertase subtilisin/kexin type...
6.
Adorni M, Galetti M, La Monica S, Incerti M, Ruffoni A, Elviri L, et al.
Int J Mol Sci . 2023 Jan; 24(2). PMID: 36674503
In tumors, the multi drug resistance phenomenon may occur through the efflux of chemotherapeutic drugs out of cancer cells, impeding their accumulation, and eventually reducing their toxicity. This process is...
7.
Kocyigit D, Zimetti F, Gurses K, Zanotti I, Marchi C, Stahlman M, et al.
Atheroscler Plus . 2023 Jan; 44:18-24. PMID: 36644669
Background And Aims: Cholesterol efflux capacity is a functional property of high-density lipoproteins (HDL) reflecting the efficiency of the atheroprotective reverse cholesterol transport process in humans. Its relationship with calcific...
8.
Bianchera A, Alomari E, Michielon A, Bazzoli G, Ronda N, Pighini G, et al.
Pharmaceutics . 2022 Dec; 14(12). PMID: 36559248
Alpha-1 antitrypsin (AAT) deficiency is a genetic disorder associated with pulmonary emphysema and bronchiectasis. Its management currently consists of weekly infusions of plasma-purified human AAT, which poses several issues regarding...
9.
Zanotti I
Int J Mol Sci . 2022 Aug; 23(16). PMID: 36012681
High-density lipoproteins (HDLs) represent physiological carriers of lipids and proteins, the activity of which has been related to cardiovascular health for decades [...].
10.
Zanotti I, Poti F, Cuchel M
Biochim Biophys Acta Mol Cell Biol Lipids . 2021 Oct; 1867(1):159065. PMID: 34637925
The ability to accept cholesterol from cells and to promote reverse cholesterol transport (RCT) represents the best characterized antiatherogenic function of HDL. Studies carried out in animal models have unraveled...